UTv Videos

“We really need to be thoughtful about how our treatment recommendations may induce financial toxicity in patients with advanced prostate cancer,” says Daniel D. Joyce, MD.

“I feel like [HIFU] provided patients this intermediary treatment option…It was less invasive than radiation and surgery, but still provided cancer control, or at least for some patients delayed the time until they needed a more radical treatment,” says Jennifer A. Linehan, MD.

“We found that treatment-related out-of-pocket costs were 18 times higher for those patients treated with novel hormonal therapies compared to those who were just on standard ADT,” says Daniel D. Joyce, MD.

“I think what becomes important with this is how we need to do our part in terms of not only engaging our non-urology colleagues to help in educating them about these most common problems in urologic conditions, but also really become [advocates] at the medical school level,” says Jessica Kreshover, MD.

“The leadership has really driven this program to be one of the best in the country,” says Casey Kowalik, MD.

Micha Yin-Zheng Cheng, MD, MPH, MS, discusses the background of the UCSF UReTER (UnderRepresented Trainees Entering Residency) Mentorship Program.

Danica May, MD, discusses positive feedback she has received from participants in the KU Department of Urology rotation.

“It’s always fun getting to interact with people from different programs and different areas and we want to make them feel as welcome as possible,” says Danica May, MD.

Among the topics touched on in the discussion are lifestyle considerations, medical therapy, and surgical options.

“Health care disparities are very complex issues; it’s not like a linear cause-and-effect relationship,” says Elisabeth M. Sebesta, MD.

“[We] found that women were spending on average, nearly $35 a week on incontinence products in the highest symptom severity, which is a huge financial burden,” says Elisabeth M. Sebesta, MD.

“With an increase in medical and surgical therapies in younger individuals, health care providers must discuss fertility preservation options prior to affirmation therapy,” says Niki Parikh, MD, MBA, MSBA.

“What we did find is that UGN-102 did not cause decrements in patient-reported urinary symptoms, bloating, flatulence, or malaise at the primary trial end point of 3 months,” says Angela M. Stover, PhD.

“These are men who are suffering in silence. Many of them are too embarrassed to ever discuss their sexual health problems,” says Mohit Khera, MD, MBA, MPH.

“We were surprised that only 43% of individuals believed fertility preservation to be important, but this could be due to the relatively low age of our respondents, with the majority being between 18 and 39 years old,” says Niki Parikh, MD, MBA, MSBA.

“It's really the overall excellence of a multidisciplinary program focused on improving patient outcomes,” says Daniel E. Spratt, MD.

“There will always be changes. I'm entering my fourth cycle of recertification, and I can tell you that none of the 3 prior cycles were similar,” says David Joseph, MD.

“Guidelines are not a rulebook; they're a framework for how to think about a particular disease,” says Edward M. Schaeffer, MD, PhD.

"I think that for patients that have high-risk features after cystectomy, they absolutely should be on nivolumab. I don't think that's a controversial statement anymore," says Benjamin J. Davies, MD.

“We…feel that this is going to be very helpful to the diplomate as far as improving their knowledge base,” says David Joseph, MD.

“What was published in May of 2022 was version 4 of the 2022 guidelines,” says Edward M. Schaeffer, MD, PhD.

“I think most panelists are happy to participate in those meetings, because generally speaking, those ad hoc meetings are done because there's a new advance in the field,” says Edward M. Schaeffer, MD, PhD.

“We recognize that we now have tools we didn't previously have that allow us to make some major changes,” says David Joseph, MD.

“We're doing probably one of the highest volume of HoLEP cases…in the United States,” says Nicole L. Miller, MD, FACS.

“I think that there's certainly recognition that HoLEP is a procedure that can be self-taught and learned. But I think the learning curve is significantly shortened if you're mentored and certainly if you're fellowship trained,” says Nicole L. Miller, MD, FACS.

“Several years ago, we eliminated the high stakes component of our exam and made it into more of an educational process,” says David Joseph, MD.

“For patients who are several years out from treatment for bladder cancer or kidney cancer, I don't think [the shortage is] going to have a clinical impact. For more acute settings, I have tried to rely a little bit more on MR urograms and ultrasound,” says Yair Lotan, MD.

“I think immunotherapy in the neoadjuvant and also in the BCG-unresponsive setting are here to stay,” says Roger Li, MD.